Oncotelic Therapeutics, Inc. reported on October 7, 2026, that company representatives presented information regarding its PDAOAI platform and hepatocellular carcinoma research at Drug Discovery 2026 in Burlingame, California. The presentations took place on October 7 and 8, 2026.
The company provided details on its PDAOAI platform, which was described by Scott Myers, the company's Product Manager. The platform utilizes a search and evidence-aggregation workflow and maintains an index of approximately 29 million PubMed abstracts. The workflow employs Partitioned Literature Aggregation to analyze defined literature groups separately before combining the findings.
Regarding hepatocellular carcinoma (HCC) research, Saran Saund, the company's Chief Business Officer, presented a four-gene mTOR-related signature. The signature consists of the genes FKBP1A, EIF4E, RRAGC, and PPARGC1A. The company stated that this signature was associated with overall survival in an exploratory discovery analysis and an independent Japanese patient cohort. However, the filing explicitly notes that these retrospective findings do not establish that the signature predicts treatment benefit from everolimus, Sapu003, or other mTOR-directed therapies.
The presentations also outlined an initiative called BIO REBOOT. This initiative invites researchers and developers to propose therapeutic research projects using the PDAOAI platform. The company stated that selected projects may qualify for startup funding and development support, subject to scientific review, available resources, and agreed terms.
